Immediate Impact
47 standout
Citing Papers
Patient‐derived xenograft model in cancer: establishment and applications
2025 Standout
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
2025 Standout
Works of Huayan Xu being referenced
Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b/2 study.
2023
A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma.
2022
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Huayan Xu | 110 | 66 | 81 | 38 | 281 | |
| Ramazan Asoğlu | 166 | 56 | 34 | 41 | 309 | |
| Adelina Yafasova | 100 | 25 | 42 | 32 | 328 | |
| Poemlarp Mekraksakit | 95 | 35 | 60 | 37 | 310 | |
| Yoan Lavie‐Badie | 200 | 39 | 95 | 44 | 309 | |
| Albert Topf | 132 | 33 | 48 | 40 | 303 | |
| Quanliang Shang | 113 | 51 | 52 | 30 | 259 | |
| Ossama Abou Hassan | 164 | 33 | 85 | 29 | 318 | |
| Andrija Matetić | 135 | 40 | 55 | 48 | 277 | |
| Muammer Karakayalı | 187 | 44 | 56 | 44 | 311 | |
| Raja Zaghlol | 99 | 39 | 102 | 25 | 315 |
All Works
Login with ORCID to disown or claim papers
Loading papers...